

# Chromosomal Localization of DNA Amplifications in Neuroblastoma Tumors Using cDNA Microarray Comparative Genomic Hybridization<sup>1</sup>

Ben Beheshti<sup>\*,†</sup>, Ilan Braude<sup>\*,†</sup>, Paula Marrano<sup>†</sup>, Paul Thorer<sup>\*,‡</sup>, Maria Zielenska<sup>\*,‡</sup> and Jeremy A. Squire<sup>\*,§,†</sup>

Departments of <sup>\*</sup>Laboratory Medicine and Pathobiology, and <sup>§</sup>Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; <sup>†</sup>Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; <sup>‡</sup>The Hospital for Sick Children, Toronto, Ontario, Canada

## Abstract

**Conventional comparative genomic hybridization (CGH) profiling of neuroblastomas has identified many genomic aberrations, although the limited resolution has precluded a precise localization of sequences of interest within amplicons. To map high copy number genomic gains in clinically matched stage IV neuroblastomas, CGH analysis using a 19,200-feature cDNA microarray was used. A dedicated (freely available) algorithm was developed for rapid *in silico* determination of chromosomal localizations of microarray cDNA targets, and for generation of an ideogram-type profile of copy number changes. Using these methodologies, novel gene amplifications undetectable by chromosome CGH were identified, and larger *MYCN* amplicon sizes (in one tumor up to 6 Mb) than those previously reported in neuroblastoma were identified. The genes *HPCAL1*, *LPIN1/KIAA0188*, *NAG*, and *NSE1/LOC151354* were found to be coamplified with *MYCN*. To determine whether stage IV primary tumors could be further subclassified based on their genomic copy number profiles, hierarchical clustering was performed. Cluster analysis of microarray CGH data identified three groups: 1) no amplifications evident, 2) a small *MYCN* amplicon as the only detectable imbalance, and 3) a large *MYCN* amplicon with additional gene amplifications. Application of CGH to cDNA microarray targets will help to determine both the variation of amplicon size and help better define amplification-dependent and independent pathways of progression in neuroblastoma.**

*Neoplasia* (2003) 5, 53–62

**Keywords:** amplicons, genomic instability, genomics, *N-myc*, high-resolution mapping, genomic profiling.

best example of a human tumor with intrinsic ability to undergo high copy number gene amplification, which typically involves a large and variable amount of DNA flanking the *MYCN* (*N-myc*) region of the genome at chromosome band 2p24 (reviewed in Ref. [2]). Both the extent and complexity of the amplified sequences associated with the *MYCN* amplicon have been difficult to characterize using traditional cytogenetic and molecular genetic mapping methods.

Recently, comparative genomic hybridization (CGH) to metaphase chromosome targets [3] has increased our understanding of the complexities of the amplicon structures associated with *MYCN* amplification in neuroblastoma [2]. CGH analyses of neuroblastomas have identified genomic imbalances commonly consisting of *MYCN* amplification, 17q gain, and deletions at 1p36, 3p, 4p, 9p, 11q, and 14q regions [4–9]. However, the minimum resolution for determining copy number gains is probably no less than 5 to 10 Mb, which is a function of both copy number and amplicon size [3,10]. Consequently, this technique can only provide a starting point for positional cloning studies, as the low resolution of conventional cytogenetics prevents precise localization of sequences of interest. Ideally, these limits are overcome using high-resolution whole genome arrays spotted with genomic clones (BACs, PACs, cosmids). However, this method of determining the location and incidence of copy number imbalances is not yet as widely available as chromosome CGH and expression microarray technologies.

An emerging platform that addresses some of the shortcomings of chromosome CGH uses microarray expression slides as target substrates for determining copy number [11]. Instead of using metaphase chromosomes, CGH is applied to arrayed short sequences of DNA bound to glass slides and probed with genomes of interest. With sufficient genetic representation on the microarray, cDNA array CGH signifi-

## Introduction

Neuroblastoma is a pediatric malignancy with an incidence rate in the U.S. of 1 in 100,000 children per year (reviewed in Ref. [1]). About one third of neuroblastomas have gene amplification, often observed cytogenetically as double minute chromosomes (dmins), and occasionally as homogeneously staining regions (HSRs). Neuroblastoma is the

Address all correspondence to: Jeremy A. Squire, PhD, Division of Cellular and Molecular Biology, Ontario Cancer Institute, Room 9-721, 610 University Ave., Toronto, Ontario, Canada M5G 2M9. E-mail: jeremy.squire@utoronto.ca

<sup>1</sup>Financial support for this project is generously provided by the James Birrell Fund for Neuroblastoma.

Received 1 July 2002; Revised 2 October 2002; Accepted 4 October 2002.

Copyright © 2003 Neoplasia Press, Inc. All rights reserved 1522-8002/03/\$25.00

cantly increases resolution for identification of key genes in regions of high copy number gain. However, because of the small size and reduced complexity of the cDNA target sequences, this approach may not have sufficient sensitivity to reproducibly detect low copy number imbalances. In this pilot study, we demonstrate the utility of cDNA array CGH for characterizing high copy number gene amplification in stage IV neuroblastoma tumors, to determine the diversity sequences coamplified with *MYCN* and the relative size of the amplicon at 2p24 using a uniformly stratified patient cohort with stage IV disease. Furthermore, we have developed dedicated software for microarray analysis and rapid *in silico* determination of chromosomal localizations of microarray cDNA targets that is essential for providing a comprehensive ideogram-type schematic of copy number changes. The use of these technologies in the analysis of amplification in neuroblastoma highlights the advantages and broad applicability of this system over conventional chromosome CGH.

## Materials and Methods

### *Patient Tissue Accrual and Polymerase Chain Reaction (PCR) of MYCN Copy Number*

Primary tumors were all clinically matched stage IV neuroblastomas, collected from patients at the Hospital for Sick Children. All samples were anonymous and were collected under the guidelines of the Hospital for Sick Children Research Ethics Board. The tumors were flash frozen directly after surgical removal and stored in liquid nitrogen. Genomic DNA from the tumor was extracted following standard protocols [12]. The amplification status of the *MYCN* gene was determined by standard quantitative PCR analyses as previously described [13]. Briefly, samples P1126, P1071, P1079, and P1008 were found to have approximately 100 or more copies of *MYCN*. Sample P1061 showed intermediate 25 to 50 copies of *MYCN*, and samples D3025, D3060, D3077-95, and D3077-97 were observed with less than 25 copies. Samples P1126, P1079, and P1071 were derived at different time points (pretreatment, post-treatment, and posttreatment inguinal lymph node metastasis, respectively) from the same patient. Table 1 lists the clinical features of the patient cohort.

### *Chromosome CGH and Fluorescence In Situ Hybridization (FISH)*

Established protocols for CGH on human metaphase chromosome spreads were followed [3]. Image capture and analysis were performed using the Vysis PathVysion and Karyotype software, respectively (Vysis, Downers Grove, IL). Telomeric and centromeric regions were excluded in the analyses due to the presence of highly repetitive genomic sequences at these sites. Ten metaphases were analyzed to create the final CGH profile with 99% confidence intervals. Where possible, FISH assessment of *MYCN* copy number in cytogenetic preparations from neuroblastoma primary tumors was performed as previously described [13]. A minimum of 100 interphase nuclei was evaluated in each cytogenetic sample for assessing the *MYCN* copy number.

### *cDNA Array CGH*

Microarrays used in this study [Human 19k2 microarray, Clinical Genomics Centre (CGC), Toronto, Ontario, Canada] contain a total of 19,200 features (Research Genetics, Invitrogen, Huntsville, AL) including 18,980 human cDNAs and 220 positive and negative control features. The features of the 19k2 microarray are arranged on two glass slides (parts A and B), each with 32 subgrids spotted over an approximate area of 18×36 mm<sup>2</sup>. All features are placed in duplicate, for a total of 38,400 spots. A complete list of the cDNA collection used for these arrays and protocols used for array construction can be found at the University Health Network CGC web site (<http://www.microarrays.ca>). It should be noted that some genes that have been reported to be part of the *MYCN* amplicon, such as *N-cym* [14] and *DDX1* [15], are not presently on the current configuration of the 19k2 microarray. Sequence verification studies being performed by the CGC allowed us to identify by BLAST analysis a small percentage of cDNAs contaminated with mitochondrial DNA (mtDNA). Identification of such sequences has allowed us to make appropriate changes and filters for our software suite (see below).

The procedure for cDNA array CGH is a modified version of the protocol published by Pollack et al. [11], and reviewed in Ref. [16]. Each microarray slide (part A and B) was blocked under a glass coverslip for 1 hour at 37°C with blocking solution (3% BSA, 4× SSC, 0.1% Tween-20) before hybridization with the denatured probe. Four micro-

**Table 1.** Clinical Information for the Patient Samples Used in This Study.

Patient sample	Gender	Age (years)	Tumor stage	Survival (months)	Primary site	Shimada histology [51]	Ploidy	1p Deletion
D3025	M	3.97	4	9.5	Adrenal	Unfavorable	Diploid	Deleted
D3060	M	4.42	4	9.5	Adrenal	Unfavorable	Diploid	Deleted
D3077-95	M	1	4	9.57	Right adrenal	N/A	Diploid	N/A
D3077-97	M	3.98	4	15	Abdomen	Unfavorable	Aneuploid	Deleted
P1061	M	1.79	4	14.83	Left adrenal	Unfavorable	Aneuploid	Deleted
P1008	F	2.37	4	15.37	Right adrenal	Unfavorable	Near tetraploid	Not deleted
P1126	M	1.96	4	14	Left adrenal	Unfavorable	Diploid	Deleted
P1071	M	1.96	4	14	Left adrenal	Unfavorable	Diploid	Deleted
P1079	M	1.96	4	14	Left adrenal	Unfavorable	Diploid	Deleted

Note all samples were derived from stage IV tumors.  
N/A, not available.

grams each of high molecular weight tumor and normal genomic DNA was separately digested with *EcoRI* for 2 hours, purified (Qiaquick PCR kit), vacuum dried, and resuspended in 25  $\mu$ l water. Random primer labeling was performed using the Bioprime Labeling kit (Invitrogen, Carlsbad, CA) according to manufacturer's instructions, with modifications to directly incorporate Cy3- and Cy5-dCTP (Amersham, Piscataway, NJ). The Cy3- and Cy5-labeled products were suppressed with 30  $\mu$ g Cot-1 DNA (Invitrogen), 100  $\mu$ g yeast tRNA (Invitrogen), and 20  $\mu$ g poly(dA-dT) (Sigma-Aldrich, St. Louis, MO), loaded onto a microcon 30 filter (Amicon, Bedford, MA), and centrifuged for 20 minutes at 5000 $\times$ *g*. The sample was recovered with 60  $\mu$ l hybridization buffer (3.4 $\times$  SSC and 0.3% SDS), and denatured at 100°C for 90 seconds. The probe was immediately chilled on ice, and allowed to preanneal at 37°C for 0.5 to 1 hour. The probe was divided and added to each microarray slide (part A and B) under a glass coverslip and sealed with rubber cement. Hybridization was at 37°C for 16 to 20 hours in a moist chamber humidified with hybridization buffer. The microarrays were washed at 65°C for 5 minutes in 2 $\times$  SSC, 0.03% SDS, followed by successive washes in 1 $\times$  and 0.2 $\times$  SSC at room temperature (5 minutes each). After air drying, the slides were scanned using an Axon GenePix 4000A confocal scanner and fluorescence intensities were quantified with GenePix Pro 3.0 software (Axon Instruments, Union City, CA). Replicate and reverse-labeling experiments were performed for selected samples.

Control genomic DNAs used in these studies included three cell lines with established levels of high copy number *MYCN* amplifications, including the retinoblastoma cell line Y79, and the neuroblastoma cell lines IMR32 and NUB-7 (American Tissue Culture Collection, Rockville, MD).

#### Bioinformatics and Analyses

Custom software scripts were developed to update the chromosome localizations for the cDNAs of the 19k2 microarray. However, any gene list having GenBank accession and I.M.A.G.E. clone [17] identifiers can be updated with this approach. The algorithm involved parsing NCBI UniGene and MapViewer databases to identify up-to-date cytoband localizations. Briefly, the UniGene database (build 147) was retrieved (<ftp://ftp.ncbi.nih.gov/>) and used to update UniGene identifiers in the gene list based on accession number. Subsequently, the accession and updated UniGene identifiers for each cDNA were cross-referenced to sequence mapping data and additional cytoband information in the MapViewer and UniGene databases, respectively. The information updates for each cDNA in the gene list include the chromosomal distance in megabases, the corresponding cytoband (based on ISCN 800 level band resolution size measurements; [18]), and a qualitative assessment score of mapping precision based on the concordance of the results gathered from the databases. Updated gene lists for these microarrays, as well as a more detailed description of the update algorithm, can be found at the laboratory's web site

**Table 2.** Genetic Representation of the 19k2 Microarray after Updating of Localization Information.

	Number of clones with position known	Number of clones with position unknown	Total microarray clones	Microarray percentage representation	Actual genome percentage representation
Chromosome 1	638	1018	1656	8.7%	7.9%
Chromosome 2	532	593	1125	5.9%	7.8%
Chromosome 3	411	558	969	5.1%	6.8%
Chromosome 4	198	507	705	3.7%	6.3%
Chromosome 5	380	432	812	4.3%	6.0%
Chromosome 6	400	487	887	4.7%	5.7%
Chromosome 7	384	488	872	4.6%	5.2%
Chromosome 8	291	336	627	3.3%	4.7%
Chromosome 9	319	402	721	3.8%	4.4%
Chromosome 10	334	369	703	3.7%	4.4%
Chromosome 11	434	489	923	4.8%	4.4%
Chromosome 12	459	457	916	4.8%	4.5%
Chromosome 13	166	178	344	1.8%	3.6%
Chromosome 14	284	312	596	3.1%	3.3%
Chromosome 15	298	309	607	3.2%	3.2%
Chromosome 16	266	342	608	3.2%	2.8%
Chromosome 17	405	415	820	4.3%	2.8%
Chromosome 18	159	151	310	1.6%	2.7%
Chromosome 19	317	490	807	4.3%	2.2%
Chromosome 20	232	204	436	2.3%	2.2%
Chromosome 21	92	114	206	1.1%	1.4%
Chromosome 22	187	181	368	1.9%	1.5%
Chromosome X	211	327	538	2.8%	5.1%
Chromosome Y	8	4	12	0.1%	1.2%
Unknown	–	2412	2412	12.7%	–
Total	7405	11575	18980	100%	100%

For each chromosome, the number of clones with known and unknown positions is listed, as well as its total representation on the microarray. For comparison, the last column identifies the total percentage size of each chromosome within the genome, based on ISCN chromosome size measurements [18]. Discrepancies between the microarray and actual representations are due to genetic redundancy on the microarray, the large number of clones with completely unknown positions, and that the percentage for actual chromosome genomic contribution includes non-coding sequences.

(<http://www.utoronto.ca/cancyto/>). Table 2 depicts the genetic representation of the 19k2 microarrays.


To facilitate analysis of results from multiple 19k2 microarray experiments, custom software was also developed. The software suite is currently comprised of four PC DOS-based components: 1) *normalize*, 2) *project*, 3) *clusterp*, and 4) *profiler*. The *normalize* software normalizes quantified Cy5 and Cy3 fluorescence intensities, with or without background subtraction, across the entire array as well as across individual subgrids. Additionally, preceding normalization, filters are applied to remove spots below user-specified thresholds for fluorescence intensity, foreground-to-background ratio, and/or spot diameter size. After normalization and filtering, duplicate spots from the microarray are averaged together. Using *project*, two or more normalized replicates of an experiment, including reverse-labelings, can be grouped together as a project. Additionally, *project* also groups together results from parts A and B of a 19k2 microarray experiment. The *clusterp* software uses selected project files to generate output that can be read by the Eisen Cluster software package (<http://rana.lbl.gov>) for two-dimensional hierarchical clustering [19,20]. Clustering was performed on genes showing hybridization in  $\geq 80\%$  of samples using an uncentered correlation similarity metric. Finally, *profiler* uses the updated chromosome localization information to generate composite chromosome plots of normalized fluorescence intensity ratios from selected projects, generating images analogous to karyotype profiles

from chromosome CGH. Note that only results for cDNA sequences with known cytoband and megabase position are plotted. To make microarray CGH methods more generally accessible to the research community, this software suite and the algorithms for automated cytoband and megabase localization of microarray cDNA features are freely available online (<http://www.utoronto.ca/cancyto/>). All experimental results are also available online as tab-delimited text files (<http://www.utoronto.ca/cancyto/NB2003/>).

## Results

### Optimization and Performance of cDNA Array CGH


The cDNA array CGH technique was optimized initially by comparing genomic DNA from IMR32, a metastatic neuroblastoma cell line with known copy number changes, and characterized by chromosome CGH (Figure 1A), against a normal reference. Replicate cDNA array CGH experiments ( $n=4$ ) including a reverse-labeling hybridization demonstrated good reproducibility and the expected *MYCN* amplification of sequences mapping to the 2p24 chromosomal region. The distribution of normalized fluorescence intensity ratios for all hybridization features ( $n=72,139$  in four hybridizations) was  $0.94 \pm 0.25$  (mean  $\pm 1$  SD), establishing a 99% confidence interval limit of 0.19 to 1.69. (Figure 1B) shows the composite CGH genomic profile of IMR32 by cDNA array CGH.



**Figure 1.** Validation of the cDNA array CGH technique. Genomic DNA from the neuroblastoma cell line IMR32 was used in both conventional CGH on metaphase chromosomes (inset, A) and cDNA array CGH (B). In the ideogram profiles generated for the cDNA array CGH results, the normalized fluorescence intensity ratios from individual replicates ( $n=4$ ) are given in yellow, and their average is plotted in red. Note the profile for chromosome Y is not shown due to the low representation of genes from this chromosome on the microarray. Chromosome CGH of IMR32 showed expected *MYCN* amplification at 2p24, with an additional amplification at 2p15 (A). These changes were also observed by cDNA array CGH, but at higher resolution (B). cDNA array CGH was able to determine that the gene amplification at 2p15 corresponded to *MEIS1*, which was recently reported using other methods.

To semiquantitate the chromosomal distributions and relative levels of copy number imbalance by CGH using both cDNA and metaphase targets, the *MYCN* normalized fluorescence intensity ratios was derived from a series of 12

neuroblastomas and cell lines against copy number measurements determined by standard quantitative PCR and Southern blot methods. Southern blot analyses of the neuroblastoma cell lines IMR32 and NUB-7 [21], and the



**Figure 2.** Comparison of resolution of chromosome CGH (A) and cDNA array CGH (B) techniques for determining genomic amplifications in a neuroblastoma patient P1071. Fluorescence in situ hybridization with labeled *MYCN* probe was used to verify copy number amplification of *MYCN* in interphase nuclei (C). (A) CGH on metaphase chromosomes showed amplification along the distal short arm of chromosome 2, but due to the limited resolution of the technique was not able to resolve the region to smaller than approximately 60 Mb (2pter–2p22). (B) cDNA array CGH profile of genomic imbalances in the same patient ( $n=3$  replicates) clearly delineated the 2p24 amplification to involve *MYCN* as well as other 2p24 genes in the vicinity of *MYCN*. Although it is expected that the technical issues dealing with low detection sensitivity will be resolved in the future, this study has focused on discussion of genes showing dosage changes of greater than 25 copies.

retinoblastoma cell line Y79 [22], have previously shown *MYCN* to have 50, 100, and 50 copies, respectively. By cDNA array CGH, the normalized fluorescence intensity ratios for *MYCN* spots were 6.5, 11.2, and 5.2, for IMR32, NUB-7, and Y79, respectively (not shown). Similarly, *MYCN* normalized fluorescence intensity ratios for the patient samples were approximately 10% of the corresponding PCR measurement. Overall, there was good correlation between the cDNA array CGH normalized fluorescence intensity ratios, and the copy number determined by PCR or Southern blot ( $R^2=0.71$ ). This analysis showed that with this sensitivity of detection, deletions or copy number gains below the level of 10 to 20 copies cannot be determined with certainty. Most likely, this sensitivity limit arises because of the small size of (intronless) cDNA targets on the arrays leading to basal background hybridization signals that mask the small signals arising from lower copy number imbalances. In contrast, multiple analyses (including use of dye switches) demonstrated that there was an excellent dynamic range at higher *MYCN* copy number with good reproducibility of copy number estimates, and with ratios that were consistent with high copy number *MYCN* amplification.

#### cDNA Array CGH of Neuroblastoma Tissues

In the next series of experiments, amplification analysis using IMR32 metaphase chromosome CGH was compared to the profiles obtained using cDNA array CGH. Chromosome CGH showed two distinct regions of amplification on chromosome 2p (Figure 1A), with the most distal centering on *MYCN* at 2p24, and the second more proximal location of gene amplification was at 2p15. The analysis of IMR32 by cDNA array CGH also identified these two amplification loci, and more clearly resolved the putative genes subject to amplification. At the 2p24 locus, the *MYCN* amplification was clearly identified by microarray CGH. In addition, the gene *NSE1* was found to be coamplified within 1 Mb telomeric to *MYCN* in IMR32. Interestingly another gene, *DNMT3A*, which is situated nearly 10 Mb centromeric to *MYCN*, was also observed to be amplified. It is noteworthy that CGH applied to metaphase preparations was unable to differ-

entiate the size of the 2p24-p23 amplicon in IMR32 with such precision.

The ratio analysis of the *MEIS1* sequences on the cDNA array clearly identified this gene in the cytoband 2p15 to be subject to amplification (Figure 1B). The *MEIS1* amplification was recently reported in IMR32 by others using different methodologies [23,24]. The normalized fluorescence intensity ratios of 5.24 and 6.85 from two distinct cDNA sequences on the microarray representing *MEIS1* would predict between 50 and 70 copies. Furthermore, the analyses also indicated that a currently unknown sequence (GenBank accession N68286) within 15 kb telomeric to *MEIS1* was also coamplified. These novel findings concerning the fine structure of the amplicons mapping to 2p in IMR32 have not been previously reported.

Microarray CGH was performed using genomic DNA derived from nine newly diagnosed neuroblastoma tumor samples. Of the nine studied, one (P1071) was subjected to both chromosome and cDNA array CGH, and *MYCN* amplification was also confirmed by interphase FISH (Figure 2, A–C). The cDNA array CGH resolved the 2p24 *MYCN* amplification boundaries to include the genes *HPCAL1* and *KIAA0188/LPIN1* that map to a 6-Mb flanking region telomeric of *MYCN*. The copy number gain of 22q shown by chromosome CGH was indicated to be due to amplification of the gene *ST13* at 22q13 by cDNA array CGH (Figure 2, A and B, respectively). The same larger *MYCN* amplicon at 2p24 was also observed in samples from the same patient, P1126 and P1079, but not in any of the other patient samples. In samples P1008 and P1061, the only amplification was *MYCN*; however, sample P1008 showed additionally amplification of a flanking unknown sequence (accession T79037) which by BLAST sequence analysis is reported to be the gene *NAG*. The remaining DNA samples did not show detectable amplification of *MYCN*, or of any other genetic loci. A summary of the amplified genes and sequences identified by cDNA array CGH in neuroblastomas is given in Table 3.

Unsupervised two-dimensional hierarchical clustering analysis was then performed on the cDNA array CGH data


**Table 3.** Genes Showing High Copy Gain Common to all Patient Samples Identified by cDNA Array CGH and Hierarchical Clustering, Some of Which are Novel and Previously Unreported in Neuroblastomas.

GenBank accession of clone	UniGene ID	Symbol	Cytoband	Approximate megabase from pter	Function/Evidence
H19826	Hs.3618	<i>HPCAL1</i>	2p24	9.7	Calcium-binding protein with similarity to hippocalin, expressed only in the brain.
R77965, H23930, N45520	Hs.81412	<i>LPIN1/KIAA0188</i>	2p24	11.8	Gene responsible for fatty liver dystrophy in mice, candidate gene for human lipodystrophy.
T79037	–	<i>unknown</i>	2p24	13.6	Sequence has as very high similarity to genomic clone RP11-516B14 containing <i>NAG</i> gene.
T65604	Hs.260855	<i>NSE1/LOC151354</i>	2p24	14.15	Novel member of the H-rev107 protein family.
R52824	Hs.25960	<i>MYCN</i>	2p24	15.45	Oncogene commonly amplified in neuroblastomas and retinoblastomas.
H03349	Hs.241565	<i>DNMT3A</i>	2p24	24.92	Gene transcriptional silencing by <i>de novo</i> DNA methylation.
N68286	Hs.109391	<i>unknown</i>	2p15	70.81	<i>Unknown</i> .
N95243, AA034934	Hs.170177	<i>MEIS1</i>	2p15	70.83	Novel homeobox gene.


Only clones that have been sequence verified are listed.

as a class discovery procedure for categorizing DNA copy number relationships between the neuroblastomas. The idea of clustering gene expression to detect functional relationships is conceptually similar to analyzing DNA copy number relationships in a group of tumors to empirically delineate classes of sequences subject to amplification. Hierarchical clustering of similarly amplified sequences may suggest close linkage of genes on common amplicon structures. In support of this idea, unsupervised hierarchical clustering was able to provide clear class distinction based on copy number amplification in neuroblastoma. As shown in Figure 3, the majority of primary tumor DNA samples were shown to branch together within the dendrogram, away from the cell line IMR32. Within the cluster of primary tumor samples, the *MYCN* low- or non-amplified samples clustered closely together (D3025, D3060, D3077-95, D3077-97). Samples P1008 and P1061 coclustered separately in this group, likely due to the high copy number of *MYCN*. Samples from the same patient (P1126, P1079) clustered together, and apart from the other patient samples, presumably due to the higher *MYCN* amplification and larger *MYCN* amplicon. The sample P1071 was derived from an undifferentiated neuroblastoma inguinal lymph node metastasis that has additional gene amplifications not present in DNA isolated from the more differentiated samples from this same patient (P1126, P1079).

In summary, hierarchical clustering permitted classification of this sample set of stage IV neuroblastoma patient tumors into three groups based on pattern of copy number changes: 1) no amplifications evident (D3025, D3060, D3077-95, D3077-97); 2) *MYCN* amplification as the only evident genomic copy number change, or a small *MYCN* amplicon (P1061, P1008); and 3) a large *MYCN* amplicon



**Figure 3.** Relationships between the neuroblastomas as defined by unsupervised two-dimensional hierarchical clustering of gene dosage change patterns derived from cDNA array CGH results. The full cluster results are provided as supplementary information online (<http://www.utoronto.ca/cancyto/NB2003/>).



**Figure 4.** Categorization of neuroblastomas based on hierarchical clustering of cDNA array CGH results, as represented by changes on chromosome 2. Groups 1, 2, and 3 are defined as having no detectable genomic amplifications; *MYCN* amplification as the only evident genomic copy number change, or a small *MYCN* amplicon; and *MYCN* amplification with additional amplification of a number of the genes in the vicinity of the *MYCN* locus; respectively.

with additional gene amplifications (P1126, P1071, P1079). These findings are summarized in Figure 4.

### Discussion

In this study, high-density cDNA microarray CGH profiling of 10 neuroblastomas was used to determine the precise chromosomal locations of gene amplifications in these tumors. There have been previous CGH studies of neuroblastoma using conventional metaphase chromosome preparations [4–9], but this analysis represents the first microarray genomic profiling of amplifications in neuroblastoma.

CGH analysis of metaphase chromosomes has enabled genome-wide detection of DNA copy number imbalances [3]. However, the relatively low resolution of chromosome CGH means that further experiments are necessary to map amplicon structures and to provide detailed positional mapping of amplified sequences of interest. Although CGH studies using genomic DNA microarrays (BAC, PAC, cosmid) have recently been published [25–31], these arrays are not yet generally available and/or at present do not have sufficient genomic coverage and therefore resolution for screening. Recently, several studies have shown the utility of cDNA microarray CGH for studying gene copy changes. Initially demonstrated by Pollack et al. [11], Kauraniemi et al. [32] have used a 636-feature chromosome 17-specific cDNA array for identifying gene copy amplifications by CGH in breast cancer cell lines. However, to date, there have been few reports documenting successful application of microarray CGH using cDNA targets.

To assess the sensitivity of cDNA array CGH analysis, PCR-quantified *MYCN* copy number was compared to amplification levels determined by cDNA array CGH. This comparison demonstrated that a minimum sensitivity of 10 to 20 copies could be obtained reproducibly, but that lower copy number alterations would escape detection. Improved sensitivity may be obtained using a recently published tyramide-based amplification protocol to augment the fluorescent signal [33]. However, one major limitation of this system is that it is not currently adaptable to two-color CGH.

After assessment of the relative sensitivity of high-density cDNA array CGH for profiling amplifications, the *MYCN* amplicon structure was determined using a panel of neuro-

blastomas. It was previously reported that the *MYCN* amplicon can range in size from 350 kb to 1 Mb [2]. These conclusions were based largely on enzymatic restriction mapping [34] or metaphase and chromatin fiber FISH mapping [21] techniques using different probes to define amplicon boundaries. However, with the advent of cDNA microarray technology combined with biological information from the Human Genome Project, a more precise examination of *MYCN* amplicon size and complexity is now possible. Our results suggest that the *MYCN* amplicon can be much larger than 1 Mb, and in fact we have observed up to 6 Mb in samples P1071, P1079, and P1126.

Altogether, the genes mapping to chromosome band 2p24 that were observed to be coamplified with *MYCN* included: hippocalcin-like 1 (*HPCAL1*), lipin 1 (*LPIN1/KIAA0188*), neuroblastoma amplified gene (*NAG*), and an unannotated gene (*NSE1/LOC151354*). Hippocalcin-like 1 has high similarity to hippocalcin on chromosome 1, which has been identified as a calcium sensor with neuronal tissue expression specificity [35,36]. Lipin 1 encodes a novel nuclear protein that although its function is currently unknown, in mouse, it is reported to be required for regulation of normal adipose tissue development [37,38]. *NAG* has previously been observed to be part of the *MYCN* amplicon, although its function is still as yet unknown [39]. The GenBank entry (accession AJ417080) for *NSE1* (unpublished) indicates this gene to be a novel member of the H-rev107 protein family, whose members include the 2A protein in picornaviruses and the cellular retinoic acid receptor responder 3 (*RARRES3/TIG3*) protein [40,41], with putative cellular antiproliferative activity. Except for *NAG*, recruitment of these genes into the *MYCN* amplicon has not been previously reported.

In addition to those genes mapping to 2p24, amplification was also detected at other genomic locations in isolated tumors. The gene *ST13* (suppressor of tumorigenicity 13), which maps to 22q13 and is reported to be an Hsp70-binding protein during steroid receptor assembly [42], was observed to be amplified in one tumor. Amplification of another gene DNA (cytosine-5) methyltransferase 3 alpha (*DNMT3A*), which is 10 Mb centromeric to *MYCN*, was observed in IMR32. This gene belongs to a family of DNA methyltransferases (DNMTs) and has a role in transcriptional regulation of gene silencing through *de novo* methylation of DNA CpG islands [43]. It has been reported that overexpression of *DNMT3A* is associated with aberrant methylation profiles in tumors as compared to normal cells [43,44]. Interestingly, amplification of mtDNA sequences was commonly observed in the tumors in the study group (data not shown). This observation suggests that increased numbers of mitochondria may be a feature of neuroblastoma oncogenesis. In keeping with this idea, it is interesting that mtDNA amplification has been reported previously in other tumors including gliomas [45–47].

To better subclassify the genomic profiles obtained in the analyses, an unsupervised hierarchical clustering approach was used to delineate three distinct groups of neuroblastomas within the study group, identified by: 1) no evident

copy number change; 2) *MYCN* amplification as the only evident genomic copy number change, or a small *MYCN* amplicon; and 3) *MYCN* amplification concomitant with additional gene amplifications, or a large *MYCN* amplicon. This is interesting, given that all the samples represent clinically similar stage IV tumors. Recently, other studies have also applied clustering algorithms to subtype tumors on the basis of the patterns of imbalances present in genomic profiling data [31,48]. In one study, self-organizing maps were used to categorize stage pT2N0 prostate carcinomas analyzed by chromosome CGH [48]. Similarly, the application of a support vector machine algorithm was recently described for subclassifying dedifferentiated and pleomorphic liposarcomas using genomic microarray CGH data [31]. Interestingly, the study also demonstrated that the genomic profiling approach was more robust in delineating tumor subclasses than the corresponding expression profiling method [31].

In conclusion, cDNA array CGH can be readily used to identify and map gene amplifications at high resolution. A diversity of amplification patterns including larger more complex *MYCN* amplicon structures was detected in a series of neuroblastomas drawn from a group with equivalent advanced stage disease. Studies in model systems have demonstrated multiple and redundant phylogenetically conserved repair pathways involved in maintenance of genome stability (reviewed in Refs. [49,50]). Unrepaired, DNA damage results in accumulating genomic rearrangements and ensuing genomic instability, is thought to underlie the acquisition of gene amplification. In the present study, cDNA array analysis identified three diverse patterns of genomic profile associated with advanced stage neuroblastoma that (within the limitations of the study group size) did not appear to impact on disease course. This observation suggests that the inherent biological differences in genomic stability within neuroblastoma do not appear to directly impact on disease course. Presently, high-resolution, high-throughput assays such as microarray CGH can be used for detailed analysis of genomic instability in other human tumors. Furthermore, the dedicated algorithms developed for this study are freely available for improved applications of microarray analyses, based on information provided by the chromosomal band locations of the microarray cDNA sequences. In the future, increased technique sensitivity and refinements to the bioinformatics of genomic profiling will greatly facilitate an improved understanding of the biology that underlies the complex patterns of genomic imbalance identified by CGH methods.

### Acknowledgement

The authors gratefully acknowledge the technical expertise of Jane Bayani.

### References

- [1] Olshan AF, and Bunin GR, Eds. (2000). Epidemiology of neuroblastoma. *Neuroblastoma* Elsevier Science, Amsterdam, pp 33–39.
- [2] George RE, and Squire JA, Eds. (2000). Structure of the *MYCN* amplicon. *Neuroblastoma* Elsevier Science, Amsterdam, pp 85–100.



- [3] Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, and Pinkel D (1992). Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. *Science* **258**, 818–21.
- [4] Van Gele M, Van Roy N, Jauch A, Laureys G, Benoit Y, Scheffhout V, De Potter CR, Brock P, Uytendaele A, Sciote R, Schuurings E, Versteeg R, and Speleman F (1997). Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridization analysis. *Eur J Cancer* **33**, 1979–82.
- [5] Vandesompele J, Van Roy N, Van Gele M, Laureys G, Ambros P, Heimann P, Devalck C, Schuurings E, Brock P, Otten J, Gysels J, De Paepe A, and Speleman F (1998). Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. *Genes Chromosomes Cancer* **23**, 141–52.
- [6] Brinkschmidt C, Poremba C, Christiansen H, Simon R, Schafer KL, Terpe HJ, Lampert F, Boecker W, and Döckhorn-Dworniczak B (1998). Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas. *Br J Cancer* **77**, 2223–29.
- [7] Breen CJ, O'Meara A, McDermott M, Mullarkey M, and Stallings RL (2000). Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. *Cancer Genet Cytogenet* **120**, 44–49.
- [8] Vandesompele J, Speleman F, Van Roy N, Laureys G, Brinkschmidt C, Christiansen H, Lampert F, Lastowska M, Bown N, Pearson A, Nicholson JC, Ross F, Combaret V, Delattre O, Feuerstein BG, and Plantaz D (2001). Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? *Med Pediatr Oncol* **36**, 5–10.
- [9] Plantaz D, Vandesompele J, Van Roy N, Lastowska M, Bown N, Combaret V, Favrot MC, Delattre O, Michon J, Benard J, Hartmann O, Nicholson JC, Ross FM, Brinkschmidt C, Laureys G, Caron H, Matthay KK, Feuerstein BG, and Speleman F (2001). Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. *Int J Cancer* **91**, 680–86.
- [10] Parente F, Gaudray P, Carle GF, and Turc-Carel C (1997). Experimental assessment of the detection limit of genomic amplification by comparative genomic hybridization CGH. *Cytogenet Cell Genet* **78**, 65–68.
- [11] Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, and Brown PO (1999). Genome-wide analysis of DNA copy-number changes using cDNA microarrays. *Nat Genet* **23**, 41–46.
- [12] Ausubel F, Brent R, Kingston R, Moore D, Seidman J, Smith J, and Sturli K (2002). *Current Protocols in Molecular Biology* John Wiley & Sons, Inc., New York, USA.
- [13] Squire JA, Thorne P, Marrano P, Parkinson D, Ng YK, Gerrie B, Chilton-Macneill S, and Zielenska M (1996). Identification of MYCN copy number heterogeneity by direct FISH analysis of neuroblastoma preparations. *Mol Diagn* **1**, 281–89.
- [14] Armstrong BC, and Krystal GW (1992). Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc. *Cell Growth Differ* **3**, 385–90.
- [15] Squire JA, Thorne PS, Weitzman S, Maggi JD, Dirks P, Doyle J, Hale M, and Godbout R (1995). Co-amplification of MYCN and a DEAD box gene (*DDX1*) in primary neuroblastoma. *Oncogene* **10**, 1417–22.
- [16] Beheshti B, Park PC, Braude I, and Squire JA (2002). Microarray CGH. *Methods Mol Biol* **204**, 191–207.
- [17] Lennon G, Auffray C, Polymeropoulos M, and Soares MB (1996). The I.M.A.G.E. consortium: an integrated molecular analysis of genomes and their expression. *Genomics* **33**, 151–52.
- [18] Mitelman F (1995). *ISCN (1995): International System for Human Cytogenetic Nomenclature*. S Karger, New York.
- [19] Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, and Levine AJ (1999). Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. *Proc Natl Acad Sci USA* **96**, 6745–50.
- [20] Eisen MB, Spellman PT, Brown PO, and Botstein D (1998). Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* **95**, 14863–68.
- [21] Pandita A, Godbout R, Zielenska M, Thorne P, Bayani J, and Squire JA (1997). Relational mapping of MYCN and DDX1 in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. *Genes Chromosomes Cancer* **20**, 243–52.
- [22] Godbout R, and Squire J (1993). Amplification of a DEAD box protein gene in retinoblastoma cell lines. *Proc Natl Acad Sci USA* **90**, 7578–82.
- [23] Jones TA, Flomen RH, Senger G, Nizetic D, and Sheer D (2000). The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines. *Eur J Cancer* **36**, 2368–74.
- [24] Spieker N, van Sluis P, Beitsma M, Boon K, van Schaik BD, van Kampen AH, Caron H, and Versteeg R (2001). The MEIS1 oncogene is highly expressed in neuroblastoma and amplified in cell line IMR32. *Genomics* **71**, 214–21.
- [25] Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, Law S, Myambo K, Palmer J, Ylstra B, Yue JP, Gray JW, Jain AN, Pinkel D, and Albertson DG (2001). Assembly of microarrays for genome-wide measurement of DNA copy number. *Nat Genet* **29**, 263–64.
- [26] Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, Moore D, Nowak N, Albertson DG, Pinkel D, Collins C, Hanahan D, and Gray JW (2001). Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. *Nat Genet* **29**, 459–64.
- [27] Bruder CE, Hirvela C, Tapia-Paez I, Franssón I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, Zucman-Rossi J, Hergersberg M, Boltshauser E, Papi L, Rouleau GA, Poptodorov G, Jordanova A, Rask-Andersen H, Kluge L, Mautner V, Sainio M, Hung G, Mathiesen T, Moller C, Pulst SM, Harder H, Heiberg A, Honda M, Niimura M, Sahlen S, Blennow E, Albertson DG, Pinkel D, and Dumanski JP (2001). High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. *Hum Mol Genet* **10**, 271–82.
- [28] Hui AB, Lo KW, Yin XL, Poon WS, and Ng HK (2001). Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. *Lab Invest* **81**, 717–23.
- [29] Daigo Y, Chin SF, Goringe KL, Bobrow LG, Ponder BA, Pharoah PD, and Caldas C (2001). Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: a new approach for the molecular analysis of paraffin-embedded cancer tissue. *Am J Pathol* **158**, 1623–31.
- [30] Wessendorf S, Fritz B, Wrobel G, Nessling M, Lampel S, Goettel D, Kuepper M, Joos S, Hopman T, Kokocinski F, Dohner H, Bentz M, Schwaenen C, and Lichter P (2002). Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. *Lab Invest* **82**, 47–60.
- [31] Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Koz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, and Lichter P (2002). Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. *Cancer Res* **62**, 2993–98.
- [32] Kauraniemi P, Barlund M, Monni O, and Kallioniemi A (2001). New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. *Cancer Res* **61**, 8235–40.
- [33] Heiskanen MA, Bittner ML, Chen Y, Khan J, Adler KE, Trent JM, and Meltzer PS (2000). Detection of gene amplification by genomic hybridization to cDNA microarrays. *Cancer Res* **60**, 799–802.
- [34] Reiter JL, and Brodeur GM (1996). High-resolution mapping of a 130-kb core region of the MYCN amplicon in neuroblastomas. *Genomics* **32**, 97–103.
- [35] Kobayashi M, Takamatsu K, Fujishiro M, Saitoh S, and Noguchi T (1994). Molecular cloning of a novel calcium-binding protein structurally related to hippocalcin from human brain and chromosomal mapping of its gene. *Biochim Biophys Acta* **1222**, 515–18.
- [36] Paterlini M, Revilla V, Grant AL, and Wisden W (2000). Expression of the neuronal calcium sensor protein family in the rat brain. *Neuroscience* **99**, 205–16.
- [37] Nagase T, Seki N, Ishikawa K, Tanaka A, and Nomura N (1996). Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (K1AA0161-K1AA0200) deduced by analysis of cDNA clones from human cell line KG-1. *DNA Res* **3**, 17–24.
- [38] Peterfy M, Phan J, Xu P, and Reue K (2001). Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. *Nat Genet* **27**, 121–24.
- [39] Wimmer K, Zhu XX, Lamb BJ, Kuick R, Ambros PF, Kovar H, Thoraval D, Motyka S, Alberts JR, and Hanash SM (1999). Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. *Oncogene* **18**, 233–38.
- [40] DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, and Nagpal S (1998). Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. *Proc Natl Acad Sci USA* **95**, 14811–15.

- [41] Hughes PJ, and Stanway G (2000). The 2A proteins of three diverse picornaviruses are related to each other and to the H-rev107 family of proteins involved in the control of cell proliferation. *J Gen Virol* **81**, 201–207.
- [42] Prapapanich V, Chen S, Nair SC, Rimerman RA, and Smith DF (1996). Molecular cloning of human p48, a transient component of progesterone receptor complexes and an Hsp70-binding protein. *Mol Endocrinol* **10**, 420–31.
- [43] Xie S, Wang Z, Okano M, Nogami M, Li Y, He WW, Okumura K, and Li E (1999). Cloning, expression and chromosome locations of the human DNMT3 gene family. *Gene* **236**, 87–95.
- [44] Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, and Jones PA (2000). Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. *Nucleic Acids Res* **28**, 2108–13.
- [45] Liang BC (1996). Evidence for association of mitochondrial DNA sequence amplification and nuclear localization in human low-grade gliomas. *Mutat Res* **354**, 27–33.
- [46] Liang BC, and Hays L (1996). Mitochondrial DNA copy number changes in human gliomas. *Cancer Lett* **105**, 167–73.
- [47] Boultonwood J, Fidler C, Mills KI, Frodsham PM, Kusec R, Gaiger A, Gale RE, Linch DC, Littlewood TJ, Moss PA, and Wainscoat JS (1996). Amplification of mitochondrial DNA in acute myeloid leukaemia. *Br J Haematol* **95**, 426–31.
- [48] Mattfeldt T, Wolter H, Kemmerling R, Gottfried HW, and Kestler HA (2001). Cluster analysis of comparative genomic hybridization (CGH) data using self-organizing maps: application to prostate carcinomas. *Anal Cell Pathol* **23**, 29–37.
- [49] Kolodner RD, Putnam CD, and Myung K (2002). Maintenance of genome stability in *Saccharomyces cerevisiae*. *Science* **297**, 552–57.
- [50] Rouse J, and Jackson SP (2002). Interfaces between the detection, signaling, and repair of DNA damage. *Science* **297**, 547–51.
- [51] Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, and Misugi K (1984). Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. *J Natl Cancer Inst* **73**, 405–16.